Quantity, purity and quality of CTCs captured using the Parsortix system shown to be superior to an alternative antibody-based approach Study supports integration of the Parsortix system into ...
NuCana plc has initiated an expansion study of its anti-cancer drug NUC-7738 combined with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors, with initial data expected in Q4 2025 ...
GUILFORD, SURREY AND PLYMOUTH MEETING, PA / ACCESS Newswire / November 5, 2025 / CELLBXHEALTH plc (AIM:CLBX)(OTCQX:ANPCY), a global leader in circulating tumour cell (CTC) intelligence, announces the ...
Icon Plc ((ICLR)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Haleon PLC (GB:HLN) announced an update on their ongoing clinical study. Haleon PLC (GB:HLN) is conducting a decentralised, real-world study titled “A Decentralised, Open-labelled, Clinical Study to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results